drugset
drugset / Trial / NCT01178125

A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of Pregnancy

NCT01178125 ↗

Phase 3 Completed 2858 enrolled Teva Branded Pharmaceutical Products R&D, Inc.
NaSingle-groupOpen-labelPrevention

Summary

This is an open-label, single treatment study. All subjects will receive 12 months of oral contraceptive therapy with DR-102. Study participants will receive physical and gynecological exams, including Pap smear. During the study, all participants will be required to complete a daily diary.

Timeline

Start
2010-08
Primary completion
2013-01
Completion
2013-01

Drugs

EvaluationDrugModalityDoseRoute
Subject DR-102 Unknown 0.01 mg Oral
Subject DR-102 Unknown 0.02 mg Oral
Subject DR-102 Unknown 0.15 mg Oral

Indications

No indication recorded.